Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Testing Immunotherapy Treatments for Recurrent Endometrial Cancer
Glossary on
off
Printer Friendly Page Testing Immunotherapy Treatments for Recurrent Endometrial Cancer

Testing Immunotherapy Treatments for Recurrent Endometrial Cancer

Clinicaltrials.gov identifier:
NCT05112601

Treatment
Treatment study for people with endometrial cancer that has returned

Study Contact Information:

For additional information, please contact: the Principal Investigator: Haider S Mahdi at NRG Oncology 412-641-5609 or mahdihs@upmc.edu

Testing Immunotherapy Treatments for Recurrent Endometrial Cancer

About the Study

This study tests the combination of two drugs compared to one drug to shrink tumors in patients with endometrial cancer that has returned after not being detected for a period of time (recurrent). The study is enrolling people with a known as .

What the Study Involves

This study involves 2 groups:

  • Group 1:
    Patients will receive both nivolumab and ipilimumab injected into the vein on day 1 of every other cycle. Cycles will repeat every three weeks and will be repeated for up to eight cycles.
  • Group 2:
    Patients will receive nivolumab injected into the vein on day 1 of each cycle. This will repeat every three weeks for every eight weeks.

Study Sites

Georgia

Augusta
Augusta University Medical Center
Contact: Site Public Contact 706-721-2388 ga_cares@augusta.edu

Iowa

Iowa City
University of Iowa/Holden Comprehensive Cancer Center
Contact: Site Public Contact 800-237-1225

Missouri

Saint Louis
Washington University School of Medicine
Contact: Site Public Contact 800-600-3606 info@siteman.wustl.edu

New Mexico

Albuquerque
University of New Mexico Cancer Center
Contact: Site Public Contact 505-925-0348 HSC-ClinicalTrialInfo@salud.unm.edu

Ohio

Cleveland
Case Western Reserve University
Contact: Site Public Contact 800-641-2422 CTUReferral@UHhospitals.org

Cleveland
Cleveland Clinic Foundation
Contact: Site Public Contact 866-223-8100 TaussigReserach@ccf.org

Oklahoma

Oklahoma City
University of Oklahoma Health Sciences Center
Contact: Site Public Contact 405-271-8777 ou-clinical-trials@ouhsc.edu

Pennsylvania

Philadelphia
NRG Oncology
Contact: Haider S. Mahdi 412-641-5609 mahdihs@upmc.edu

Pittsburgh
University of Pittsburgh Cancer Institute (UPCI)
Contact: Site Public Contact 412-647-8073

Rhode Island

Providence
Women and Infants Hospital
Contact: Site Public Contact 401-274-1122

Virginia

Charlottesville
University of Virginia Cancer Center
Contact: Site Public Contact 434-243-6303 uvacancertrials@hscmail.mcc.virginia.edu

Washington

Seattle
Fred Hutchinson Cancer Research Center
Contact: Site Public Contact 800-804-8824

This Study is Open To:

People 18 years or older who:

  • have detectable recurrent endometrial cancer with (deficient mismatch repair)
  • have received 1-2 prior lines of treatment, but must have been stopped at least 4 weeks prior to the start of the trial
  • have recovered from the effects of any recent surgeries or cancer treatments
  • agree to use contraceptives prior to the study and five months following following the study, as well as test negative for pregnancy or not be breastfeeding
  • do not have detectable HBV, HIV or HCV
This Study is Not Open To:

People who:

  • have a diagnosis of endometrial serous cancer
  • are receiving immunosuppressive therapy
  • have an active autoimmune disease or weak immune systems that may be unable to respond to the treatment
  • are pregnant or unwilling to stop nursing
  • have had prior therapy with a treatment similar to the therapy being used in the trial
  • have had a history of allergic reactions to materials similar to the treatment being given in the study